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Objective: Thyroid hormone concentrations can be disturbed during critical illness. Our aim 
was to determine changes in thyroid hormone concentrations during neonatal extracorporeal 
membrane oxygenation (ECMO). 
Study design: We included 21 ECMO-treated neonates. Age-specific standard deviation 
scores (SDS) of free and total thyroxine (FT4; TT4), reverse and total triiodothyronine (rT3; 
TT3), thyroid-stimulating hormone (TSH) and thyroxine-binding globulin (TBG) were 
determined at six fixed time-points. Data were analyzed using general linear models. 
Results: At baseline, mean SDS FT4 (-0.78, 95% confidence interval: -1.37 to -0.19), TT4 (-
1.97, 95% confidence interval: -2.76 to -1.18), TT3 (-0.88, 95% confidence interval: -1.13 to  
-0.63), TSH (-2.14, 95% confidence interval: -2.93 to -1.35) and TBG (-3.52, 95% confidence 
interval: -4.55 to -2.50) were low with high mean SDS rT3 (0.53, 95% confidence interval: 
0.28 to 0.78). One hour after start ECMO, TT4, TSH and TBG had further declined; 12 hours 
after start ECMO TT3 had declined (all p<0.05). After this decline, mean SDS TSH increased 
to the baseline level 12 h after start ECMO (-2.50, 95% confidence interval: -3.22 to -1.79), 
and was higher than baseline 48 h after start ECMO (-0.56, 95% confidence interval: -1.29 to 
0.17). This TSH increase was followed by increases in TT4 and TT3. FT4 remained constant 
within the normal range during ECMO. 
Conclusions: Thyroid hormone concentrations before ECMO were suggestive of non-
thyroidal illness syndrome (NTIS). During ECMO, increases in TSH, TT4 and TT3 after an 
initial decline possibly reflect spontaneous restoration of the hypothalamic–pituitary–thyroid 
axis. FT4 remained constant within the normal range. This suggests that thyroxine therapy is 





Thyroid hormone concentrations can be affected by several factors including gestational age,1 
cardiac surgery,2, 3 use of drugs such as dopamine,4 and critical illness.5-7 Critically ill patients 
typically present with lower concentrations of total triiodothyronine (TT3) and total thyroxine 
(TT4), increased reverse triiodothyronine (rT3) and low to normal thyroid-stimulating 
hormone (TSH) concentrations, which is known as non-thyroidal illness syndrome (NTIS) or 
euthyroid sick syndrome.5-7 The magnitude of changes in TT3 and TT4 concentrations has 
been related to the severity of illness. Both low TT3 and low TT4 have been associated with 
adverse patient outcomes such as increased mortality in neonatal, pediatric and adult 
patients.8-14  
Recently we reported that 67.3% of neonates screened during extracorporeal 
membrane oxygenation (ECMO) had an aberrant screening result for congenital 
hypothyroidism.15 The one study so far on thyroid hormone concentrations during neonatal 
ECMO found a decline in all thyroid hormone concentrations in 14 critically ill neonates 
directly after the start of ECMO.16 It is not known, however, whether and how thyroid 
hormone concentrations change during and after neonatal ECMO, and whether there are any 
potential therapeutic consequences of changes. Therefore, we determined longitudinal 












We included 21 neonates with a diagnosis of meconium aspiration syndrome (MAS) or 
congenital diaphragmatic hernia (CDH), which are the two most common indications for 
neonatal ECMO treatment.17 Neonates were admitted to either of the two ECMO centers in 
the Netherlands (Erasmus MC-Sophia Children’s Hospital, Rotterdam or Radboud University 
Medical Center-Amalia Children’s Hospital, Nijmegen), both level III university hospitals. 
ECMO therapy was initiated in case of reversible severe respiratory failure with an estimated 
mortality risk of480% as described by Stolar et al. and on the standardized CDH-EURO 
consortium consensus treatment protocol.18, 19   
Relevant clinical data were collected including gestational age, birth weight, gender, 
age at start ECMO, duration of ECMO, neonatal screening results for congenital 
hypothyroidism and survival. Severity of illness was estimated with the Pediatric Risk of 
Mortality III (PRISM III) score and the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) 
score.20, 21 PRISM III is a physiology-based score for predicting the mortality risk in pediatric 
intensive care unit (PICU) patients. It is calculated from the most abnormal values of 17 
physiologic variables obtained in the first 24 hours of PICU care (score range: 0-74).20 The 
PELOD-2 is a descriptive score that allows daily assessment of the severity of multiple organ 
dysfunction syndrome in PICU patients. It includes 10 variables involving five organ 
dysfunctions with a score range of 0-33.21 PELOD-2 scores were calculated for the 24 hours 
prior to blood sampling. Use of dopamine ≤8 hours prior to blood sampling was recorded 
because dopamine affects thyroid hormone concentrations within the first hours after 
initiation of treatment, and pre-treatment concentrations are reached within hours after 
discontinuation.22 None of the patients received supplemental levothyroxine at any time-point. 
At 2 years of age, the Bailey Scales of Infant Development -Second Edition- Dutch version 
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was used to assess cognitive outcomes of patients using the mental development index score. 
The mean score of the mental development index is 100 with a standard deviation (standard 
deviation) of 15.23 Informed consent was obtained from parents. Ethical approval for this 
study was obtained from both local Ethics Committees (CMO 2005/253). 
 
ECMO procedure 
In the Erasmus MC-Sophia Children’s Hospital, the ECMO circuit was primed with 
erythrocyte concentrate, Ringer’s solution, albumin, Tris buffer, sodium bicarbonate, calcium 
gluconate and heparin. In the Radboud University Medical Center-Amalia Children’s 
Hospital, the ECMO circuit was primed with erythrocyte concentrate, fresh frozen plasma 
(FFP), sodium bicarbonate and heparin. The total prime volume was approximately 350 ml in 
both centers. Once the circuit was fully primed, ECMO cannulation was performed. The 
pediatric intensivist or neonatologist and pediatric surgeon decided on the choice of ECMO 
modality (veno-venous or veno-arterial). 
 
Thyroid function measurements 
Blood was taken from an arterial catheter at six fixed time-points: 1 hour prior to ECMO 
(baseline value); 1, 12, 48 and 72 hours after start of ECMO; >24 hours after cessation of 
ECMO. Plain tubes were centrifuged and serum was stored at -20 °C. Free thyroxine (FT4), 
TT4, TT3 and TSH concentrations were determined using chemiluminescence assays (Vitros 
ECI; Ortho Clinical-Diagnostics, Rochester, New York, U.S.A.). rT3 was measured by 
radioimmunoassay (ZenTech S.A., Liége, Belgium). Thyroxine-binding globulin (TBG) was 
measured on an Immulite XPi system (Siemens Healthcare Diagnostics B.V., Los Angeles, 
California, USA). The intra- and interassay coefficients of variation were <5.4% for FT4, 
<6.4% for TT4, <8.7% for rT3, <4.3% for TT3, <4.1% for TSH and <6.4% for TBG. Thyroid 
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hormone concentrations and TBG were calculated into standard deviation scores (SDS) using 
age-specific reference values.24 The normal range was considered as between -2 SDS and +2 
SDS compared to the reference values, which are shown in supplementary table 1. 
 
Statistical analyses 
Baseline characteristics of MAS and CDH patients were compared using the Fisher’s exact 
test for categorical variables. The independent samples t-test was used for normally 
distributed variables, and the Mann-Whitney U-test for continuous variables that were not 
normally distributed. Differences in thyroid hormone concentrations at baseline between 
survivors and non-survivors were compared using the Mann-Whitney U-test. We used general 
linear models to describe the longitudinal changes in thyroid hormone concentrations and 
TBG. The dependent variables in these general linear models were the SDS of FT4, TT4, rT3, 
TT3, TSH and TBG. The independent variables were gestational age, diagnosis, use of 
dopamine ≤8 hours prior to the laboratory measurement, treatment center (use of FFP) and 
time-point (treated as a categorical variable). A random intercept was used in the general 
linear models to account for the within-subject correlations. Multicollinearity was assessed by 
calculating correlations between independent variables. The results of the general linear 
models are presented using the estimated marginal means, which are the predicted values of 
the dependent variable adjusted for covariates in the model, and the associated 95% 
confidence interval. To estimate the effect of critical illness, PELOD-2 score and survival 
were added as independent variables in subsequent analyses. The statistical tests were two-
sided and used a significance level of 0.05. All analyses were performed using SPSS 21.0 for 







We included 21 ECMO-treated neonates diagnosed with either MAS (n=11) or CDH (n=10). 
The CDH patients had a significantly lower gestational age than the MAS patients, and were 
all treated with veno-arterial ECMO (table 1). The CDH patients had a significantly higher 
PRISM III score than the MAS patients. Mental development index scores of CDH and MAS 
patients were within the normal range of the Dutch norm population (within 1 SDS of the 
mean). One MAS patient could not be tested because of severe mental disabilities due to 
perinatal asphyxia. Eighteen patients were screened for congenital hypothyroidism in 
accordance with the Dutch neonatal screening protocol (others: screening too late (n=2); 
screening result missing (n=1)). Two of the three (66.7%) patients screened before ECMO 
had an aberrant initial screening result. Seven of the 12 (58.3%) patients screened during 
ECMO had an aberrant initial screening result. None were diagnosed with congenital 
hypothyroidism. The three patients screened after ECMO all had a normal screening result. 
Three (14.3%) patients died from pulmonary hypertension after ECMO decannulation: two 












Table 1 Patient characteristics 





Gestational age (weeks) 40.7±0.6 37.6±1.6 <0.001 
Birth weight (grams) 3.38±0.37 3.00±0.62 0.10 
Male 6 (54.5%)  5 (50.0%) 1.00 
PRISM III score (first 24 hours of PICU admission) 13±6 21±7 0.01 
Veno-arterial ECMO 4 (36.4%) 10 (100%) 0.004 
Age start ECMO (days) 3 (1-4) 1 (1-2) 0.31 
Duration of ECMO therapy (hours) 146±80 165±65 0.56 
MDI1 92±82 93±163 0.97 
Data are expressed as mean±standard deviation, median (interquartile range) or number (percentage).  
1 The Bailey Scales of Infant Development –Second Edition- Dutch version was used to assess mental 
development index in survivors. 
2 Nine MAS patients were tested: one patient died and one patient could not be tested because of 
severe mental disabilities due to perinatal asphyxia. 
3 Seven CDH patients were tested: two patients died and one patient was lost to follow-up 
Abbreviations: CDH=congenital diaphragmatic hernia; ECMO=extracorporeal membrane 
oxygenation; MAS=meconium aspiration syndrome; MDI=mental development index; 
PICU=pediatric intensive care unit; PRISM III=Pediatric Risk of Mortality III. 
 
Thyroid hormone and thyroxine-binding globulin concentrations at baseline 
Mean baseline values of FT4, TT4, TT3, TSH and TBG were significantly below the 
reference norm (SDS=0), and rT3 was significantly higher than the norm (table 2). Mean 
baseline values of TSH and TBG were abnormally low before ECMO. Baseline values did not 
differ between MAS patients and CDH patients or between patients in the two different 
treatment centers (data not shown). At baseline, the three non-survivors had lower median 
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TT3 SDS (-1.32, interquartile range (IQR): -1.46 to -1.29 vs -0.85, IQR: -1.10 to -0.63) and 
lower median TBG SDS (-5.70, IQR: -6.17 to -4.90 vs -2.71, IQR: -3.89 to -1.69) than 
survivors (both p=0.03). 
 
Table 2 Thyroid hormone and thyroxine-binding globulin concentrations at baseline compared 
with the reference norms 
SDS of ECMO patients 
n=21 
p-value 
FT4  -0.78 (-1.37 to -0.19) 0.01 
TT4  -1.97 (-2.76 to -1.18) <0.001 
TT3  -0.88 (-1.13 to -0.63) <0.001 
rT3  0.53 (0.28 to 0.78) <0.001 
TSH  -2.14 (-2.93 to -1.35) <0.001 
TBG  -3.52 (-4.55 to -2.50) <0.001 
Data are presented using the estimated marginal means (associated 95% confidence interval). 
Abbreviations: ECMO=extracorporeal membrane oxygenation; FT4=free thyroxine; rT3=reverse 
triiodothyronine; SDS=standard deviation score; TBG=thyroxine-binding globulin; TSH=thyroid-
stimulating hormone; TT3=total triiodothyronine; TT4=total thyroxine. 
 
Thyroid hormone and thyroxine-binding globulin concentrations during neonatal ECMO 
Figure 1 shows the changes in thyroid hormone concentrations. One hour after start of 
ECMO, all thyroid hormone concentrations and TBG showed a downward slope. Mean TT4, 
rT3, TSH and TBG significantly declined 1 hour after start of ECMO (p=0.003, p=0.002, 
p=0.02, p<0.001, respectively). Mean TT3 was significantly lower than baseline 12 hours 
after start of ECMO (p=0.02). After this initial decline, first TSH increased to baseline 12 
hours after start of ECMO. TT4, rT3, TT3 and TBG reached their baseline values 48 hours 
after start of ECMO. After the cessation of ECMO, TT3 and TSH concentrations were 
significantly higher than baseline (p=0.009, p<0.001, respectively). Mean TBG was still 
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abnormally low after cessation of ECMO. FT4 concentrations did not significantly change 

























Figure 1. Changes in thyroid hormone and thyroxine-binding globulin concentrations 
during neonatal extracorporeal membrane oxygenation 
A. Changes in FT4, TT4 and TSH concentrations  
 




C. Changes in TBG concentration 
 
Estimated marginal means with error bars representing the 95% confidence intervals were 
plotted.  
Pre-ECMO: 1 hour prior to ECMO (baseline value); +1: 1 hour after start of ECMO; +12: 12 
hours after start of ECMO; +48: 48 hours after start of ECMO; +72: 72 hours after start of 
ECMO; Post-ECMO: >24 hours after cessation of ECMO.  
* Indicates a significant change compared with the baseline value.  
Abbreviations: ECMO=extracorporeal membrane oxygenation; FT4=free thyroxine; 
rT3=reverse triiodothyronine; TBG=thyroxine-binding globulin; TSH=thyroid-stimulating 
hormone; TT3=total triiodothyronine; TT4=total thyroxine. 
 
Clinical variables associated with thyroid hormone and thyroxine-binding globulin 
concentrations 
The estimated coefficients of time-point, gestational age, diagnosis of CDH, dopamine use 
and treatment center (use of FFP) on thyroid hormone concentrations are given in 
supplementary table 2. The numbers of children that used dopamine are shown in 
supplementary table 3. Time-point had a significant effect on all thyroid hormone and TBG 
concentrations, except FT4. Use of FFP was positively associated with TSH and TBG, but 
was negatively associated with FT4. A diagnosis of CDH was negatively associated with 
TSH. PELOD-2 score or survival had no significant associations with thyroid hormone 
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concentrations or TBG (data not shown). Assessment of multicollinearity revealed a strong 
correlation between gestational age and diagnosis (r=0.85). Excluding diagnosis as a covariate 


























We found that the concentrations of FT4, TT4, TT3, TSH and TBG were already low and the 
rT3 concentration already high in critically ill neonates prior to the start of ECMO, 
resembling the pattern described in NTIS.5-7 The biologically active hormone FT4 was 
statistically significantly below the reference norm, but it remained within the normal range. 
After an initial decline directly after start ECMO, first TSH increased to a value above 
baseline 48 hours after ECMO. This TSH increase was followed by increases in TT4 and 
TT3, possibly reflecting clinical recovery with restoration of the hypothalamic–pituitary-
thyroid axis.  
Stewart et al.16 studied thyroid hormone concentrations during ECMO in 14 neonates 
with severe respiratory failure from different causes, and also found a decline in all thyroid 
hormone concentrations directly after the start of ECMO. Further, a recent study in pediatric 
patients undergoing cardiac surgery with cardiopulmonary bypass specifically addressed the 
thyroid response in a subgroup of 57 neonates.3 Similar to our results, TSH strongly declined 
after surgery. However, they also found a small drop in FT4. Agus et al.25 found that low 
concentrations of thyroid hormones are present in ECMO prime fluid. In the current study, the 
prime volume was 350 ml. We think that the immediate decline of thyroid hormone 
concentrations can be ascribed to a dilutional effect. Based on the average birth weights in our 
study, we estimated that the dilutional factor in MAS was 55% (350/(350+287)x100%) and in 
CDH was 58% (350/(350+255)x100%). We think that this small difference in dilutional 
factor did not cause a significant difference in the decline of thyroid hormone levels between 
both groups. However, a larger difference in dilutional factor could lead to a different 
response. Agus et al.25 suggested that concentrations of thyroid hormones would be higher 
when FFP is used in the prime fluid. Indeed we found a positive association between TSH and 
TBG and the use of FFP. However, this positive association was not found for TT4, rT3 and 
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TT3, and contrary to this suggestion, we found that the use of FFPs was associated with lower 
FT4 levels. From this study, we cannot make a definite conclusion about the effect of the of 
FFP in prime fluid on thyroid hormone levels.  
Hemodilution may not be the only explanation for this decline in thyroid hormone 
concentrations. The severe decline in TBG concentration could also be explained by a global 
inflammatory response with consequent capillary leakage, which occurs during the initial 
phases of cardiopulmonary bypass and ECMO.26-28 This capillary leak allows plasma proteins 
to move from the intravascular to the extravascular space, which lowers plasma protein 
concentrations. 
Other factors contributing to the changes in thyroid hormone concentrations may be 
the severity of critical illness and use of dopamine. Previous studies in neonates have found a 
relation between low TT3 and low TT4 and adverse patient outcomes such as increased 
mortality, longer duration of mechanical ventilation and longer hospital stay.12-14 Therefore, 
we expected thyroid hormone concentrations to be lower in neonates with a greater severity of 
illness. Indeed, we found lower concentrations of TT3 and TSH at baseline in non-survivors. 
However, we did not find an association between the PELOD-2 score or survival and thyroid 
hormone concentrations in the general linear model. This could be due to the relatively small 
sample size. Secondly, although the PELOD-2 score has been validated for PICU patients,21, 
29 the score is affected by treatment such as ventilator settings and use of vasoactive drugs. 
Therefore, it does not solely reflect the severity of illness. Possibly, the PELOD-2 score does 
not distinguish enough between treatment effects and severity illness in this specific group of 
ECMO-treated neonates. Furthermore, dopamine could have played a role, as it has been 
found to suppress TSH concentrations.22 Dopamine could be discontinued in most patients 
during ECMO, and we think this indeed played a role in the TSH increase during ECMO. 
However, we did not find a significant association between dopamine and thyroid hormone 
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concentrations, which may be due to the influence of other factors that potentially affect 
thyroid hormone concentrations during ECMO. In the present study, the combination of low 
TT3, TT4 and TSH concentrations prior to the start of ECMO indicates an aberrant feedback 
regulation of the hypothalamic–pituitary–thyroid axis, as has been previously described 
during NTIS.5-7 During ECMO, however, first the TSH concentration significantly increased, 
which was later followed by an increase in TT4 and TT3. Other studies have found the same 
pattern of TSH, TT4 and TT3 increases at the start of restoration of the hypothalamic 
pituitary–thyroid axis.30, 31  
Therefore, we think these changes in thyroid hormone concentrations during ECMO 
suggest clinical recovery with restoration of the hypothalamic–pituitary–thyroid axis. In a 
previous study we found a higher incidence of aberrant screening results for congenital 
hypothyroidism in neonates screened before (73.1%) or during ECMO (67.3%) than in 
neonates screened after (31.4%) ECMO.15 In the present study, aberrant screening results 
were found only in neonates screened before or during ECMO. None of the children with an 
aberrant screening result had congenital hypothyroidism. Because thyroid hormone 
concentrations significantly changed during ECMO, we recommend to repeat thyroid function 
tests after ECMO. Thyroid function tests should be repeated before the age of 14 days, 
however, because thyroxine treatment started later than this age can lead to intellectual 
disabilities.32  
Treatment of low thyroid hormone concentrations during NTIS remains a matter of 
debate. As thyroid hormone is important for neurodevelopment during early life, a low 
concentration during this period could possibly affect neurodevelopmental outcomes. Yet, 
studies on thyroid supplementation therapy in infants with hypothyroxinemia of prematurity 
found no beneficial effect.33 Further, a recent study found that transient hypothyroxinemia of 
prematurity was not associated with adverse neurodevelopmental outcomes at the age of 19 
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years.34 A randomized controlled trial in pediatric patients undergoing cardiac surgery found 
that T3 supplementation in patients <5 months of age was associated with reduced time of 
mechanical ventilation.35 However, T3 supplementation in pediatric patients undergoing 
cardiopulmonary bypass has not been found to improve their long-term neurodevelopmental 
outcomes.36 We found a constant FT4 concentration during ECMO, which was only slightly 
lower than the reference norm. Further, cognitive outcomes of MAS and CDH patients were 
similar to cognitive outcomes of the norm population, except for one MAS patient with severe 
perinatal asphyxia. This, in combination with the lack of evidence for thyroid replacement 
therapy and the increases in thyroid hormone concentrations during ECMO suggest that early 
treatment is not required during ECMO. However, larger studies with long-term follow-up of 
neurodevelopmental outcomes should be performed to draw definite conclusions.  
A strength of this study is the determination of all thyroid hormone concentrations and 
TBG at fixed time-points before, during and after neonatal ECMO. Furthermore, it is the first 
study that calculated these concentrations into SDS using recently established age-specific 
reference values.24 A limitation of this study is that we did not measure thyroid hormone 
concentrations in the prime fluid used during ECMO. Thyroid hormone concentrations in 
prime fluid could have varied. Measurements of thyroid hormone concentrations in the prime 
fluid would have given more information about the hemodilution effect during ECMO.  
In conclusion, we found that thyroid hormone disturbances similar to NTIS were 
present in critically ill neonates prior to the start of ECMO. After an initial decline directly 
after the start of ECMO, first TSH increased, followed by TT4 and TT3. This may reflect 
restoration of the hypothalamic–pituitary–thyroid axis during ECMO. FT4 remained constant 
within the normal range during the ECMO course. These results suggest that thyroid hormone 
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Supplementary table 1 Age-specific reference values for thyroid hormone and thyroxine-binding 
globulin levels in neonates published by Lem et al.24 
 Age -2 SDS -1 SDS 0 SDS +1 SDS +2 SDS 
FT4 (pmol/L) Day of birth 12.12 15.81 21.78 32.65 56.54 
 1 day-7 days 12.32 15.91 21.61 31.65 52.54 
 8 days-1 month 12.81 16.12 21.12 29.28 44.33 
TT4 (nmol/L) Day of birth 75.26 99.44 132.38 177.64 240.37 
 1 day-7 days 75.90 99.96 132.64 177.36 239.10 
 8 days-1 month 77.93 101.62 133.44 176.47 235.16 
TT3 (nmol/L) Day of birth 0.30 1.23 2.18 3.13 4.09 
 1 day-7 days 0.32 1.25 2.18 3.13 4.08 
 8 days-1 month 0.39 1.29 2.21 3.13 4.06 
rT3 (nmol/L) Day of birth 0.30 0.48 0.87 1.88 5.51 
 1 day-7 days 0.30 0.48 0.86 1.82 5.20 
 8 days-1 month 0.30 0.47 0.83 1.67 4.36 
TSH (mU/L) Day of birth 2.43 3.84 6.44 11.75 24.03 
 1 day 1.90 3.21 5.54 9.76 17.58 
 2 days 1.40 2.61 4.64 7.94 13.10 
 3 days 0.94 2.03 3.75 6.24 9.65 
 4 days 0.60 1.48 2.85 4.63 6.82 
 5 days-7 days 0.58 1.18 2.14 3.57 5.58 
 8 days-1 month 0.58 1.18 2.14 3.57 5.57 
TBG (mg/L) Day of birth 19.17 23.34 28.68 35.61 44.70 
 1 day-7 days 19.16 23.34 28.67 35.59 44.68 
 8 days-1 month 19.12 23.28 28.61 35.51 44.59 
24 Lem AJ, de Rijke YB, van Toor H, de Ridder MA, Visser TJ, Hokken-Koelega AC. Serum thyroid 
hormone levels in healthy children from birth to adulthood and in short children born small for 
gestational age. J Clin Endocrinol Metab. 2012;97:3170-3178. 
Abbreviations: FT4=free thyroxine; SDS=standard deviation score; TT4=total thyroxine; TT3=total 












Supplementary table 2 Associations between thyroid hormone and thyroxine-binding globulin 
concentrations and clinical variables 






FT4  Time-point (compared to baseline):  
1 hour after start ECMO 
12 hours after start ECMO 
48 hours after start ECMO 









-0.72 to 0.70 
-1.25 to 0.23 
-0.73 to 0.76 
-0.65 to 0.93 
-0.76 to 0.90 
0.53 
 Gestational age (weeks) 0.20 -0.07 to 0.47 0.15 
 Diagnosis of CDH 0.44 -0.58 to 1.46 0.37 
 Use of dopamine -0.26 -0.84 to 0.31 0.36 
 Center that used FFP -0.67 -1.26 to -0.07 0.03 
TT4  Time-point (compared to baseline):  
1 hour after start ECMO 
12 hours after start ECMO 
48 hours after start ECMO 









-2.48 to -0.54 
-2.27 to -0.27 
-1.81 to 0.23 
-1.37 to 0.77 
-0.29 to 1.96 
<0.001 
 Gestational age (weeks) 0.26 -0.09 to 0.62 0.13 
 Diagnosis of CDH -0.38 -1.69 to 0.93 0.55 
 Use of dopamine -0.20 -0.96 to 0.57 0.61 
 Center that used FFP 0.67 -0.10 to 1.43 0.08 
rT3  Time-point (compared to baseline):  
1 hour after start ECMO 
12 hours after start ECMO 
48 hours after start ECMO 









-0.76 to -0.18 
-0.32 to 0.29 
-0.44 to 0.17 
-0.52 to 0.13 
-0.44 to 0.23 
0.03 
 Gestational age (weeks) -0.02 -0.15 to 0.11 0.74 
 Diagnosis of CDH 0.18 -0.30 to 0.66 0.44 
 Use of dopamine 0.07 -0.18 to 0.31 0.58 
 Center that used FFP -0.21 -0.50 to 0.07 0.13 
TT3  Time-point (compared to baseline):  
1 hour after start ECMO 
12 hours after start ECMO 
48 hours after start ECMO 









-0.60 to 0.04 
-0.72 to -0.07 
-0.36 to 0.30 
-0.39 to 0.31 
0.13 to 0.86 
<0.001 
 Gestational age (weeks) 0.10 -0.002 to 0.20 0.05 
 Diagnosis of CDH -0.02 -0.39 to 0.34 0.90 
 Use of dopamine -0.19 -0.43 to 0.04 0.11 
 Center that used FFP 0.11 -0.11 to 0.32 0.30 
TSH  Time-point (compared to baseline):  
1 hour after start ECMO 
12 hours after start ECMO 
48 hours after start ECMO 









-1.77 to -0.17 
-1.20 to 0.48 
0.72 to 2.44 
1.61 to 3.42 
2.06 to 3.97 
<0.001 
 Gestational age (weeks) -0.38 -0.88 to 0.12 0.13 
23 
 
 Diagnosis of CDH -2.25 -4.10 to -0.40 0.02 
 Use of dopamine -0.50 -1.23 to 0.24 0.18 
 Center that used FFP 1.37 0.27 to 2.46 0.02 
TBG  Time-point (compared to baseline):  
1 hour after start ECMO 
12 hours after start ECMO 
48 hours after start ECMO 









-5.92 to -3.76 
-4.39 to -2.13 
-1.99 to 0.31 
-1.44 to 1.00 
-0.02 to 2.55 
<0.001 
 Gestational age (weeks) 0.12 -0.49 to 0.74 0.68 
 Diagnosis of CDH -1.33 -3.60 to 0.94 0.24 
 Use of dopamine -0.32 -1.29 to 0.65 0.52 
 Center that used FFP 1.63 0.29 to 2.97 0.02 
Abbreviations: CDH=congenital diaphragmatic hernia; ECMO=extracorporeal membrane 
oxygenation; FFP=fresh frozen plasma; FT4=free thyroxine; rT3=reverse triiodothyronine; 






















Supplementary table 3 Number of patients that used dopamine during extracorporeal 
membrane oxygenation 
Time-point Use of dopamine 
1 hour before start ECMO (baseline) 94.7% (18/19) 
1 hour after start ECMO 94.7% (18/19) 
12 hours after start ECMO 55% (11/20)  
48 hours after start ECMO 52.6% (10/19)  
72 hours after start ECMO 50.0% (8/16) 
Post-ECMO 42.9% (6/14) 
Abbreviation: ECMO=extracorporeal membrane oxygenation. 
 
 
 
 
